HBV News and Research

RSS

Daily aspirin therapy linked to reduced risk of HBV‐related liver cancer

A new study presented this week at The Liver Meeting – held by the American Association for the Study of Liver Diseases – found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus‐related liver cancer.

20 Oct 2017

Report sheds light on global market for infectious disease immunoassays

Kalorama Information says that infectious disease immunoassays beat the IVD market and the overall IVD market in terms of revenue growth. Immunoassays are tests that are based on the binding of antibodies to antigens to identify the presence of a substance.

16 Oct 2017

Shortage of Hepatitis B vaccine - prioritization of vaccinations announced in UK

According to a recent announcement made by Public Health England, there is a global shortage of vaccines used against hepatitis B infection. This announcement is followed up by a “prioritisation guidance” which means that persons who are at greatest risk of getting hepatitis B are to be vaccinated on priority if they have not received the vaccine before.

7 Aug 2017

FDA approves new treatment for all HCV genotypes 1-6

The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis.

3 Aug 2017

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

1 Aug 2017

World Hepatitis Day – gearing towards eliminating viral hepatitis by 2030

July 28th is marked as world hepatitis day. The world is united in elimination of viral hepatitis by 2030. The World Health Organization (WHO) has published new data from 28 countries today and shown that nearly 70% of the world hepatitis burden is borne by these countries.

27 Jul 2017

ECDC highlights need to scale-up efforts for eliminating viral hepatitis in Europe

An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection.

26 Jul 2017

Princeton scientists test cell-culture system to aid study of HBV infections

Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections

25 Jul 2017

FDA approves fixed-dose combination tablet for treating adults with chronic hepatitis C

The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.

18 Jul 2017

Study estimates number of cancer deaths in China attributable to potentially modifiable risk factors

A new report finds more than half of all cancer deaths in men in 2013 in China and more than a third of those in women were attributable to a group of potentially modifiable risk factors: smoking, alcohol, nutrition, weight, physical activity, and infections.

6 Jul 2017

Survey finds wide variation in hepatitis B, C testing policy and practice across the EU/EEA

The survey results suggest a wide variation in existing national testing policy and practice when it comes to hepatitis B and C - with overall limited monitoring of testing, diagnosis, and treatment across EU/EEA Member States.

1 Jun 2017

Statins may provide favorable effects in patients with HBV- or HCV-related cirrhosis

Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis.

8 May 2017

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.

26 Apr 2017

Statins may provide favorable outcomes to patients with HBV- or HCV-related cirrhosis

24 Apr 2017

WHO Global Hepatitis Report reveals goal to eliminate viral hepatitis by 2030

The World Health Organization (WHO) has published the first-ever Global Hepatitis Report. The World Hepatitis Alliance (WHA) welcomes the publication, which is a follow-up to WHO’s Global Strategy on Viral Hepatitis, and has set the goal to eliminate viral hepatitis as a public health threat by 2030.

21 Apr 2017

FDA grants approval for two drugs to treat hepatitis C virus in children

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.

7 Apr 2017

ECDC guidance aims to improve antenatal screening for infections to avoid mother-to-child transmission

Transmission of infections with HIV, hepatitis B, syphilis or rubella from mother to child before and during birth as well as in infancy still occur across Europe - despite existing prevention methods.

21 Mar 2017

Quest Diagnostics introduces new HBV test service to help evaluate patient’s response to drug therapies

24 Jan 2017

A test to evaluate Hepatitis B therapy launched by Quest Diagnostics

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus (HBV). The first test of its kind available in the United States, the test is significant because it may help physicians tailor more effective treatments for the up to 2.2 million individuals infected with HBV.

23 Jan 2017

Georgia State University, GeoVax join forces to advance development of Hepatitis B therapeutic vaccine

The Georgia State University Research Foundation has entered into a research collaboration agreement with GeoVax Labs, Inc., a Georgia-based biotechnology company developing human vaccines, to advance development of a therapeutic vaccine for treatment of chronic Hepatitis B infections.

18 Jan 2017